Latest News for: sll

Edit

Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL

Citizen Tribune 09 Dec 2025
LBA-3. Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL. First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients ....
Edit

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

PR Newswire 09 Dec 2025
BRUIN CLL-313 is the first prospective, randomized Phase 3 study examining the efficacy and safety of a non-covalent BTK inhibitor, pirtobrutinib, exclusively in patients with treatment-naïve CLL/SLL.
Edit

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

PR Newswire 03 Dec 2025
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor ... Lilly is studying Jaypirca in CLL/SLL in multiple Phase 3 studies.
Edit

Rise in SLL crimes in Nagaland: NCRB report

Hindustan Times 01 Oct 2025
Rise in SLL crimes in Nagaland ... The report shows SLL crimes surged from 445 cases in 2021, 584 in 2022 and 849 cases in 2023, the report said ... The SLL crime rate for Nagaland was 38 per lakh population, still lower than the national average of 178.0.
  • 1

Article Search

tools
×
×
×
×